Eli Lilly drug tirzepatide meets weight-loss goals in obesity trial

SEE YOU LATER. >>> JOE, WE HAVE NEWS JUST OUT FROM ELI LILLY WE HAVE MEG TIRRELL WITH US. MEG. >> Reporter: ANDREW, ANTICIPATED CLINICAL TRIAL IN OBESITY FROM ELI LILLY. THE DRUG IS UNDER REVIEW FOR TYPE-TWO DIABETES WITH THE FDA THEY WERE LOOKING AT THE DRUG FOR WEIGHT LOSS. THEY FOUND IT IMMEMET THE GOALSN THE STUDY. THE WEIGHT LOSS THEY SHOWED INCREASED WITH THE DOSE AT THE HIGHEST DOSE IT LED TO 23% AVERAGE WEIGHT LOSS OVER THE COURSE OF THE STUDY. THAT IS UP FROM 16% ON THE LOW DOSE COMPARED TO 2.5% FOR PLACEBO. THEY SAID THIS IS THE FIRST TIME THE DRUG DELIVERED MORE THAN 20% WEIGHT LOSS ON AVERAGE IN THE STUDY. THE EVENTS LOOKS LIKE GI ISSUES WHICH WERE MILD TO MODERATE. OBESITY IS A SPACE THAT DRUGMAKERS HAVE BEEN WORKING ON FOR DECADES. BANK OF AMERICA IS ESTIMATES THE MARKET COULD BE BIG FOR LILLY. $6.4 BILLION IN SALES FOR THE DRUG IN OBESITY ALONE. OF COURSE,.

As found on YouTube